Suzanne Sawochka Hooper Sells 4,580 Shares of Jazz Pharmaceuticals PLC (JAZZ) Stock

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) EVP Suzanne Sawochka Hooper sold 4,580 shares of the firm’s stock in a transaction that occurred on Thursday, July 20th. The shares were sold at an average price of $160.00, for a total transaction of $732,800.00. Following the transaction, the executive vice president now directly owns 32,322 shares in the company, valued at approximately $5,171,520. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Suzanne Sawochka Hooper also recently made the following trade(s):

  • On Friday, June 23rd, Suzanne Sawochka Hooper sold 420 shares of Jazz Pharmaceuticals PLC stock. The shares were sold at an average price of $160.00, for a total transaction of $67,200.00.
  • On Tuesday, May 9th, Suzanne Sawochka Hooper sold 2,500 shares of Jazz Pharmaceuticals PLC stock. The shares were sold at an average price of $160.00, for a total transaction of $400,000.00.
  • On Thursday, April 27th, Suzanne Sawochka Hooper sold 2,500 shares of Jazz Pharmaceuticals PLC stock. The shares were sold at an average price of $160.00, for a total transaction of $400,000.00.

Shares of Jazz Pharmaceuticals PLC (JAZZ) traded down 1.10% during mid-day trading on Friday, hitting $144.40. The stock had a trading volume of 1,596,250 shares. Jazz Pharmaceuticals PLC has a 1-year low of $95.80 and a 1-year high of $163.75. The firm has a market capitalization of $8.67 billion, a PE ratio of 22.24 and a beta of 1.10. The stock’s 50-day moving average is $153.65 and its 200-day moving average is $147.43.

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) last announced its earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported $1.72 earnings per share for the quarter, missing analysts’ consensus estimates of $1.85 by $0.13. Jazz Pharmaceuticals PLC had a return on equity of 22.75% and a net margin of 25.69%. The business had revenue of $394.39 million during the quarter, compared to the consensus estimate of $410.83 million. During the same quarter in the prior year, the company earned $2.67 earnings per share. Jazz Pharmaceuticals PLC’s revenue was up 3.5% compared to the same quarter last year. Equities analysts expect that Jazz Pharmaceuticals PLC will post $10.87 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: This news story was originally posted by BNB Daily and is the property of of BNB Daily. If you are viewing this news story on another website, it was copied illegally and republished in violation of US & international trademark and copyright laws. The correct version of this news story can be accessed at https://www.baseball-news-blog.com/2017/08/19/suzanne-sawochka-hooper-sells-4580-shares-of-jazz-pharmaceuticals-plc-jazz-stock-updated-updated-updated.html.

Institutional investors have recently bought and sold shares of the company. FMR LLC boosted its position in Jazz Pharmaceuticals PLC by 11.4% in the second quarter. FMR LLC now owns 8,290,410 shares of the specialty pharmaceutical company’s stock worth $1,289,159,000 after buying an additional 849,348 shares during the last quarter. Vanguard Group Inc. boosted its position in Jazz Pharmaceuticals PLC by 3.4% in the second quarter. Vanguard Group Inc. now owns 4,677,223 shares of the specialty pharmaceutical company’s stock worth $727,308,000 after buying an additional 153,908 shares during the last quarter. BlackRock Inc. boosted its position in Jazz Pharmaceuticals PLC by 3,163.9% in the first quarter. BlackRock Inc. now owns 3,215,159 shares of the specialty pharmaceutical company’s stock worth $466,615,000 after buying an additional 3,116,652 shares during the last quarter. Janus Capital Management LLC boosted its position in Jazz Pharmaceuticals PLC by 46.8% in the first quarter. Janus Capital Management LLC now owns 1,470,245 shares of the specialty pharmaceutical company’s stock worth $213,367,000 after buying an additional 468,940 shares during the last quarter. Finally, Bank of New York Mellon Corp boosted its position in Jazz Pharmaceuticals PLC by 3.2% in the first quarter. Bank of New York Mellon Corp now owns 1,447,760 shares of the specialty pharmaceutical company’s stock worth $210,114,000 after buying an additional 44,973 shares during the last quarter. Hedge funds and other institutional investors own 87.22% of the company’s stock.

A number of equities analysts have recently commented on JAZZ shares. Zacks Investment Research lowered shares of Jazz Pharmaceuticals PLC from a “hold” rating to a “sell” rating in a research report on Tuesday, May 2nd. Mizuho dropped their price target on shares of Jazz Pharmaceuticals PLC from $150.00 to $144.00 and set a “neutral” rating on the stock in a research report on Wednesday, May 31st. Cowen and Company reissued an “outperform” rating and issued a $190.00 price target on shares of Jazz Pharmaceuticals PLC in a research report on Wednesday, May 10th. Cantor Fitzgerald reissued a “buy” rating on shares of Jazz Pharmaceuticals PLC in a research report on Thursday, April 27th. Finally, Deutsche Bank AG set a $178.00 price objective on shares of Jazz Pharmaceuticals PLC and gave the stock a “buy” rating in a research note on Monday, July 17th. One analyst has rated the stock with a sell rating, two have given a hold rating and nineteen have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $182.72.

About Jazz Pharmaceuticals PLC

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

Insider Buying and Selling by Quarter for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply